Paradigm Pharmaceuticals Inc

Management

The senior managements of Paradigm Pharmaceuticals Inc. (Paradigm Pharma) and its operations across its markets consist of executives and managers  with a wide ranging experience in both multinational and branded pharmaceutical generics companies.

The company is led by its founder Amal Naj, who previously was a Senior Vice President at Pfizer Inc.'s worldwide headquarters in New York and prior to that a career journalist on the staff of the Wall Street Journal in the U.S. In addition to overseeing Paradigm Pharma, Mr. Naj is also the CEO of its affiliated company, Berlin Pharmaceutical Industry Co. Ltd., a leading branded-generics company in Thailand.

The Company

Paradigm Pharma was founded in 2008 with the business concept of offering both prevention and treatment, especially in chronic diseases. The pharmaceutical industry has generally been focused on treating sickness; prevention hasn't been its raison d'être nor its mission, rightly or wrongly. Paradigm Pharma is engaged in  identifying and offering nutraceuticals (natural products with scientific and clinical support ) side-by-side with pharmaceuticals with the aim of offering preventative and treatment options to lessen human dependence on pharmaceuticals.

The company licenses-in products from a roster of leading international companies, and secures supplies at lowest possible costs so it can offer medicines and dietary supplements at highly affordable prices to patients, especially in poor countries in Asia, a cornerstone of its founding mission. 

Paradigm Pharma is a closely-held U.S. company, with autonomously operated units in Asia, and markets products under its own brandnames.

Paradigm Objective & Mission

The company has established as its operating objective delivering medicines and supplements at prices that maximize patients' access to its products. It includes selective "Patient Access Programs" for critical life-saving drugs offered at cost in poor regions through local medical institutions.

Guiding Principles

I. COMPLIANCE IN MARKETING OF PRODUCTS 

Paradigm and its sales and medical representatives shall not promote or influence sales with improper and unethical incentives to physicians and pharmacists. From top managment to the ranks of sales and marketing, all colleagues are required to always compliy with the Company's "Business Code of Conduct" ("Orange Book") in their daily conduct of business inside and outside the Company. Colleagues are required periodically to participate in workshops to familiar themeselves with integiry and ehtical behaviors expected of them in their interactions with healthcare professionals, and are required to confirm their compliance by annually signing the Company's Compliance Notification Notice.

II. EXPANDING ACCESS

Paradigm shall endeavor to increase access to its products for financially poor patients by offering deep discounts, and, for critical life-saving drugs, at cost through selective "Patient Access Programs" in partnership with local medical institutions.

III. PARTNERING WITH HEALTHCARE PROFESSIONALS

Interacting with healthcare professionals helps us understand and stay up to date on treatment options, efficacy of one medicine over another in same therapeutic area, and obtain other valuable real-life information on prescription medicines and dietary supplements. As this helps us better serve our patients, Paradigm has established programs to engage leading healthcare professionals to share information and medical knowledge with their peers in therapies in which our products are available for treatment.      

IV. MARKETING OF NUTRACEUTICALS/DIETARY SUPPLEMENTS

Most of the dietary supplements, from vitamins and minerals to probiotcs and herbal medicines, are yet to be subjectied to the clinical scrutiny given to pharmaceuticals to establsh their conclusive therapeutic benefits. Yet there exists emperical and scientific evidence, and in some cases convincing clinical evidene, for a number of these natural products. In advancing the concept of Paradigm as a "Complementary Medicines Company," we market only the products with active compounds whose benefits are supported by sufficient scientific and clinical evidence. We make exception for some which although not studied clinically but have been in use for centuries. We are however forthright in telling where the evidence of benefit is  insufficient or inconclusive.